Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells.

Romeo C, Weber MC, Zarei M, DeCicco D, Chand SN, Lobo AD, Winter JM, Sawicki JA, Sachs JN, Meisner-Kober N, Yeo CJ, Vadigepalli R, Tykocinski ML, Brody JR.

Mol Cancer Res. 2016 Jul;14(7):599-611. doi: 10.1158/1541-7786.MCR-15-0448. Epub 2016 Apr 6.

2.

Can empathy, other personality attributes, and level of positive social influence in medical school identify potential leaders in medicine?

Hojat M, Michalec B, Veloski JJ, Tykocinski ML.

Acad Med. 2015 Apr;90(4):505-10. doi: 10.1097/ACM.0000000000000652.

PMID:
25629944
3.

Identifying potential engaging leaders within medical education: The role of positive influence on peers.

Michalec B, Veloski JJ, Hojat M, Tykocinski ML.

Med Teach. 2015 Jul;37(7):677-683. doi: 10.3109/0142159X.2014.947933. Epub 2014 Aug 26.

PMID:
25155553
4.

Fn14•TRAIL effectively inhibits hepatocellular carcinoma growth.

Aronin A, Amsili S, Prigozhina TB, Tzdaka K, Rachmilewitz J, Shani N, Tykocinski ML, Dranitzki Elhalel M.

PLoS One. 2013 Oct 10;8(10):e77050. doi: 10.1371/journal.pone.0077050. eCollection 2013.

5.

Energy transfer in "parasitic" cancer metabolism: mitochondria are the powerhouse and Achilles' heel of tumor cells.

Martinez-Outschoorn UE, Pestell RG, Howell A, Tykocinski ML, Nagajyothi F, Machado FS, Tanowitz HB, Sotgia F, Lisanti MP.

Cell Cycle. 2011 Dec 15;10(24):4208-16. doi: 10.4161/cc.10.24.18487. Epub 2011 Dec 15.

6.

CD40·FasL and CTLA-4·FasL fusion proteins induce apoptosis in malignant cell lines by dual signaling.

Orbach A, Rachmilewitz J, Shani N, Isenberg Y, Parnas M, Huang JH, Tykocinski ML, Dranitzki-Elhalel M.

Am J Pathol. 2010 Dec;177(6):3159-68. doi: 10.2353/ajpath.2010.100301. Epub 2010 Nov 18.

7.

Inhibition of effector function but not T cell activation and increase in FoxP3 expression in T cells differentiated in the presence of PP14.

Ochanuna Z, Geiger-Maor A, Dembinsky-Vaknin A, Karussis D, Tykocinski ML, Rachmilewitz J.

PLoS One. 2010 Sep 23;5(9):e12868. doi: 10.1371/journal.pone.0012868.

8.

Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis.

Razmara M, Hilliard B, Ziarani AK, Murali R, Yellayi S, Ghazanfar M, Chen YH, Tykocinski ML.

Am J Pathol. 2009 Feb;174(2):460-74. doi: 10.2353/ajpath.2009.080462. Epub 2009 Jan 15.

9.

CTLA-4 x Ig converts naive CD4+CD25- T cells into CD4+CD25+ regulatory T cells.

Razmara M, Hilliard B, Ziarani AK, Chen YH, Tykocinski ML.

Int Immunol. 2008 Apr;20(4):471-83. doi: 10.1093/intimm/dxn007. Epub 2008 Feb 13.

PMID:
18272926
10.

Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer.

Tone Y, Furuuchi K, Kojima Y, Tykocinski ML, Greene MI, Tone M.

Nat Immunol. 2008 Feb;9(2):194-202. Epub 2007 Dec 23.

PMID:
18157133
11.

CTLA-4 . FasL induces early apoptosis of activated T cells by interfering with anti-apoptotic signals.

Orbach A, Rachmilewitz J, Parnas M, Huang JH, Tykocinski ML, Dranitzki-Elhalel M.

J Immunol. 2007 Dec 1;179(11):7287-94.

12.

OX40 gene expression is up-regulated by chromatin remodeling in its promoter region containing Sp1/Sp3, YY1, and NF-kappa B binding sites.

Tone Y, Kojima Y, Furuuchi K, Brady M, Yashiro-Ohtani Y, Tykocinski ML, Tone M.

J Immunol. 2007 Aug 1;179(3):1760-7.

13.

CD40.FasL inhibits human T cells: evidence for an auto-inhibitory loop-back mechanism.

Dranitzki-Elhalel M, Huang JH, Sasson M, Rachmilewitz J, Parnas M, Tykocinski ML.

Int Immunol. 2007 Apr;19(4):355-63. Epub 2007 Feb 20.

PMID:
17314083
14.

CTLA-4.FasL inhibits allogeneic responses in vivo.

Dranitzki-Elhalel M, Huang JH, Rachmilewitz J, Pappo O, Parnas M, Schmidt W, Tykocinski ML.

Cell Immunol. 2006 Feb;239(2):129-35. Epub 2006 Jul 7.

PMID:
16828466
15.

alpha2,6-Sialylation promotes binding of placental protein 14 via its Ca2+-dependent lectin activity: insights into differential effects on CD45RO and CD45RA T cells.

Ish-Shalom E, Gargir A, André S, Borovsky Z, Ochanuna Z, Gabius HJ, Tykocinski ML, Rachmilewitz J.

Glycobiology. 2006 Mar;16(3):173-83. Epub 2005 Nov 3.

PMID:
16269626
16.

Pathology as the enabler of human research.

Crawford JM, Tykocinski ML.

Lab Invest. 2005 Sep;85(9):1058-64.

17.

Pregnancy zone protein is a carrier and modulator of placental protein-14 in T-cell growth and cytokine production.

Skornicka EL, Kiyatkina N, Weber MC, Tykocinski ML, Koo PH.

Cell Immunol. 2004 Nov-Dec;232(1-2):144-56.

PMID:
15882859
18.

Differential regulation of Th1/Th2 cytokine responses by placental protein 14.

Mishan-Eisenberg G, Borovsky Z, Weber MC, Gazit R, Tykocinski ML, Rachmilewitz J.

J Immunol. 2004 Nov 1;173(9):5524-30.

19.

New designs for cancer vaccine and artificial veto cells: an emerging palette of protein paints.

Tykocinski ML, Chen A, Huang JH, Weber MC, Zheng G.

Immunol Res. 2003;27(2-3):565-74. Review.

PMID:
12857999
20.

CTLA-4. FasL induces alloantigen-specific hyporesponsiveness.

Elhalel MD, Huang JH, Schmidt W, Rachmilewitz J, Tykocinski ML.

J Immunol. 2003 Jun 15;170(12):5842-50.

21.

Quantitative interplay between activating and pro-apoptotic signals dictates T cell responses.

Chen A, Zheng G, Tykocinski ML.

Cell Immunol. 2003 Feb;221(2):128-37.

PMID:
12747954
22.

Negative regulation of T cell activation by placental protein 14 is mediated by the tyrosine phosphatase receptor CD45.

Rachmilewitz J, Borovsky Z, Riely GJ, Miller R, Tykocinski ML.

J Biol Chem. 2003 Apr 18;278(16):14059-65. Epub 2003 Jan 29.

23.

Lipid length controls antigen entry into endosomal and nonendosomal pathways for CD1b presentation.

Moody DB, Briken V, Cheng TY, Roura-Mir C, Guy MR, Geho DH, Tykocinski ML, Besra GS, Porcelli SA.

Nat Immunol. 2002 May;3(5):435-42. Epub 2002 Apr 8.

PMID:
11938350
24.

Focal localization of placental protein 14 toward sites of TCR engagement.

Rachmilewitz J, Borovsky Z, Mishan-Eisenberg G, Yaniv E, Riely GJ, Tykocinski ML.

J Immunol. 2002 Mar 15;168(6):2745-50.

25.

A rheostatic mechanism for T-cell inhibition based on elevation of activation thresholds.

Rachmilewitz J, Riely GJ, Huang JH, Chen A, Tykocinski ML.

Blood. 2001 Dec 15;98(13):3727-32.

PMID:
11739178
26.

Induction of antitumor immunity via intratumoral tetra-costimulator protein transfer.

Zheng G, Chen A, Sterner RE, Zhang PJ, Pan T, Kiyatkin N, Tykocinski ML.

Cancer Res. 2001 Nov 15;61(22):8127-34.

27.

Properties of exogenously added GPI-anchored proteins following their incorporation into cells.

Premkumar DR, Fukuoka Y, Sevlever D, Brunschwig E, Rosenberry TL, Tykocinski ML, Medof ME.

J Cell Biochem. 2001;82(2):234-45.

PMID:
11527149
28.
29.

The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma.

Ariel I, Sughayer M, Fellig Y, Pizov G, Ayesh S, Podeh D, Libdeh BA, Levy C, Birman T, Tykocinski ML, de Groot N, Hochberg A.

Mol Pathol. 2000 Dec;53(6):320-3.

30.

Glycerolphosphoinositide anchors for membrane-tethering proteins.

Fayen JD, Tykocinski ML, Medof ME.

Methods Enzymol. 2000;327:351-68. No abstract available.

PMID:
11044996
31.

alpha2-macroglobulin modulates the immunoregulatory function of the lipocalin placental protein 14.

Riely GJ, Rachmilewitz J, Koo PH, Tykocinski ML.

Biochem J. 2000 Oct 15;351 Pt 2:503-8.

32.

Glycosyl-phosphatidylinositol reanchoring unmasks distinct antigen-presenting pathways for CD1b and CD1c.

Geho DH, Fayen JD, Jackman RM, Moody DB, Porcelli SA, Tykocinski ML.

J Immunol. 2000 Aug 1;165(3):1272-7.

34.

Protein transfer of glycosyl-phosphatidylinositol (GPI)-modified murine B7-1 and B7-2 costimulators.

Brunschwig EB, Fayen JD, Medof ME, Tykocinski ML.

J Immunother. 1999 Sep;22(5):390-400.

PMID:
10546154
35.
36.

Expression of the imprinted H19 oncofetal RNA in epithelial ovarian cancer.

Tanos V, Prus D, Ayesh S, Weinstein D, Tykocinski ML, De-Groot N, Hochberg A, Ariel I.

Eur J Obstet Gynecol Reprod Biol. 1999 Jul;85(1):7-11.

PMID:
10428315
37.

Placental protein 14 functions as a direct T-cell inhibitor.

Rachmilewitz J, Riely GJ, Tykocinski ML.

Cell Immunol. 1999 Jan 10;191(1):26-33.

PMID:
9918684
38.

A receptor for the lipocalin placental protein 14 on human monocytes.

Miller RE, Fayen JD, Chakraborty S, Weber MC, Tykocinski ML.

FEBS Lett. 1998 Oct 9;436(3):455-60.

39.

Negative signaling by anti-HLA class I antibodies is dependent upon two triggering events.

Fayen J, Huang JH, Ferrone S, Tykocinski ML.

Int Immunol. 1998 Sep;10(9):1347-58.

PMID:
9786434
40.

Antisense modulation of the ICAM-1 phenotype of a model human bone marrow stromal cell line.

Weber MC, Groger RK, Tykocinski ML.

Exp Cell Res. 1998 Oct 10;244(1):239-48.

PMID:
9770366
41.

Non-glycosylated human B7-1(CD80) retains the capacity to bind its counter-receptors.

Chen A, Meyerson HJ, Salvekar A, Tykocinski ML.

FEBS Lett. 1998 May 29;428(3):127-34.

43.

Developmentally imprinted genes as markers for bladder tumor progression.

Cooper MJ, Fischer M, Komitowski D, Shevelev A, Schulze E, Ariel I, Tykocinski ML, Miron S, Ilan J, de Groot N, Hochberg A.

J Urol. 1996 Jun;155(6):2120-7.

PMID:
8618347
44.

A novel class of cell surface glycolipids of mammalian cells. Free glycosyl phosphatidylinositols.

Singh N, Liang LN, Tykocinski ML, Tartakoff AM.

J Biol Chem. 1996 May 31;271(22):12879-84.

45.

Cell-surface engineering with GPI-anchored proteins.

Medof ME, Nagarajan S, Tykocinski ML.

FASEB J. 1996 Apr;10(5):574-86. Review.

PMID:
8621057
46.

Functional dissociation of CD8 alpha's Ig homologue and connecting peptide domains.

Meyerson HJ, Huang JH, Fayen JD, Tsao HM, Getty RR, Greenspan NS, Tykocinski ML.

J Immunol. 1996 Jan 15;156(2):574-84.

PMID:
8543808
47.

Platelet immunoregulatory factors.

Tykocinski ML, Xiong N, Morrow DM.

Stem Cells. 1996;14 Suppl 1:240-5. Review.

48.

Antigen-presenting cell engineering. The molecular toolbox.

Tykocinski ML, Kaplan DR, Medof ME.

Am J Pathol. 1996 Jan;148(1):1-16. Review. No abstract available.

49.

Glycosylphosphatidylinositol-modified murine B7-1 and B7-2 retain costimulator function.

Brunschwig EB, Levine E, Trefzer U, Tykocinski ML.

J Immunol. 1995 Dec 15;155(12):5498-505.

PMID:
7499830
50.

Lessons to be learned from hematopoietic malignancies. Workshop report from the Division of Research Grants, National Institutes of Health.

Matrisian LM, Tykocinski ML, Padarathsingh M.

Am J Pathol. 1995 Nov;147(5):1519-21. No abstract available.

Supplemental Content

Loading ...
Support Center